Earnings
Many of the big biopharma companies reported fourth-quarter and year-end earnings this week. If there’s a theme among them, it seems lower earnings per share are forecast for the year.
Lonza reported a 9% organic sales, 12% organic CORE EBITDA and 14% organic CORE EBIT growth.
It’s no secret that the global biopharma and life sciences industry is large. Sometimes the immense size of the industry can lead fascinating news tidbits to fall through the cracks, particularly those from smaller companies scattered across the globe. This week BioSpace will launch a new roundup of news from companies across the globe.
Novartis Chief Executive Officer Vas Narasimhan said 2018 was a year of reimagining for Switzerland-based Novartis. It was a year when the company focused its capital and resourced on developing breakthrough medicines.
For 2018, Pfizer reported revenues of $53.6 billion, which was 2 percent operational growth. The fourth quarter brought in $14 billion, which was 5 percent operational growth.
Roche announced that it was discontinuing two of its Alzheimer’s Phase III trials, CREAD I and 2, after a pre-planned interim analysis.
AbbVie reported a loss of $1.83 billion for the fourth quarter of 2018. Overall revenues were up for the full year, however, hitting $32.75 billion compared to $28.2 billion in 2017.
Any 2018 BMS news is going to tend to get lost in the shadow of its $74 billion acquisition of Celgene. Still, it looked like a good year, with fourth-quarter revenue up 10% and full-year revenues up 9%.
In its year-end financial report, Johnson & Johnson (J&J) predicted product sales for 2019 to range from $80.4 billion to $81.2 billion, about $1 to $2 billion below what Wall Street analysts projected. The company thinks this will largely be due to increased biosimilar competition.
Adocia confirmed its financial calendar for 2019 with a change in date of the annual shareholder’s meeting.
PRESS RELEASES